tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Ovid Therapeutics announces results for Phase 1 study of OV329
PremiumThe FlyOvid Therapeutics announces results for Phase 1 study of OV329
16d ago
Ovid Therapeutics Regains Nasdaq Compliance
Premium
Company Announcements
Ovid Therapeutics Regains Nasdaq Compliance
1M ago
Ovid Therapeutics’ Promising Pipeline and Strategic Developments Justify Buy Rating
Premium
Ratings
Ovid Therapeutics’ Promising Pipeline and Strategic Developments Justify Buy Rating
2M ago
Ovid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating
PremiumRatingsOvid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating
2M ago
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market
Premium
Company Announcements
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market
2M ago
Ovid Therapeutics reports Q2 EPS (6c), consensus (15c)
Premium
The Fly
Ovid Therapeutics reports Q2 EPS (6c), consensus (15c)
2M ago
Ovid Therapeutics Approves Key Proposals at Annual Meeting
PremiumCompany AnnouncementsOvid Therapeutics Approves Key Proposals at Annual Meeting
3M ago
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
Premium
Company Announcements
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
4M ago
Ovid enters agreement with Immedica for sale of future ganaxolone royalties
Premium
The Fly
Ovid enters agreement with Immedica for sale of future ganaxolone royalties
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100